AstraZeneca Rating Reiterated by UBS AG (AZN)
AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities research analysts at UBS AG in a research note issued to investors on Friday, American Banking and Market News reports. They currently have a GBX 3,600 ($56.07) target price on the stock. UBS AG’s price objective would indicate a potential upside of 10.89% from the company’s current price.
AZN has been the subject of a number of other recent research reports. Analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Wednesday, August 21st. They now have a GBX 3,328 ($51.83) price target on the stock. Separately, analysts at Morgan Stanley downgraded shares of AstraZeneca to an “underweight” rating in a research note to investors on Thursday, August 15th. They now have a GBX 3,200 ($49.84) price target on the stock, down previously from GBX 3,400 ($52.95). Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Tuesday, August 13th. They now have a GBX 3,425 ($53.34) price target on the stock.
Twelve analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of GBX 3,210.25 ($50.00).
AstraZeneca (LON:AZN) traded up 1.98% on Friday, hitting GBX 3246.50. The stock had a trading volume of 1,781,289 shares. AstraZeneca has a 52 week low of GBX 2786.00 and a 52 week high of GBX 3544.50. The stock has a 50-day moving average of GBX 3262.42 and a 200-day moving average of GBX 3227.. The company’s market cap is £40.646 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.